Table 1.

Polymorphisms of transporters that influence the efficacy of platinum drugs

Protein	Gene	Genetic polymorphisms or expression level (EL) that influences the outcome of platinum-based therapy
Uptake of platinum drugs
OCT1	SLC22A1	c.181C > T, c.480C > G, c.1022C > T, c.1222A > G, c.1390G > A, c.1463G > T
OCT2	SLC22A2	c.160C > T, c.481 T > C, c.493A > G, c.495G > A, c.808G > T, c.890C > G, c.1198C > T, c.1294A > C
OCT3	SLC22A3	EL
CTR1	SLC31A1	rs10981694 A>C
CTR2	SLC31A2

Efflux of platinum drugs
MATE1	SLC47A1	p.Gly64Asp and p.Val480Met: reduced transport of oxaliplatin
MATE2	SLC47A2	p.Gly211Val
ATP7A	ATP7A (MNK)	c.2299G > C (p.Val767Leu) and c.4390A > G (p.Ile1464Val)
ATP7B	ATP7B (WND)	c.1216G > T (p.Ala406Ser), c.1366G > C (p.Val456Leu), c.2495A > G (p.KLys32Arg), c.2785A > G (p.Ile929Val), c.2855G > A (p.Arg952Lys), c.2871delC (P957PfsX9), c.3419 T > C (p.Val1140Ala), c.3836A > G (p.Asp1279Gly), c.3886G > A (p.Asp1296Asn) and c.3889G > A (p.Val1297Ile)

EL = expression level